These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

705 related items for PubMed ID: 18723475

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Effect of the drug transporters ABCG2, Abcg2, ABCB1 and ABCC2 on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPA.
    Marchetti S, Pluim D, van Eijndhoven M, van Tellingen O, Mazzanti R, Beijnen JH, Schellens JH.
    Invest New Drugs; 2013 Oct; 31(5):1125-35. PubMed ID: 23315030
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Enhanced brain accumulation of pazopanib by modulating P-gp and Bcrp1 mediated efflux with canertinib or erlotinib.
    Minocha M, Khurana V, Qin B, Pal D, Mitra AK.
    Int J Pharm; 2012 Oct 15; 436(1-2):127-34. PubMed ID: 22688250
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Compartment-specific roles of ATP-binding cassette transporters define differential topotecan distribution in brain parenchyma and cerebrospinal fluid.
    Shen J, Carcaboso AM, Hubbard KE, Tagen M, Wynn HG, Panetta JC, Waters CM, Elmeliegy MA, Stewart CF.
    Cancer Res; 2009 Jul 15; 69(14):5885-92. PubMed ID: 19567673
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Co-administration strategy to enhance brain accumulation of vandetanib by modulating P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp1/Abcg2) mediated efflux with m-TOR inhibitors.
    Minocha M, Khurana V, Qin B, Pal D, Mitra AK.
    Int J Pharm; 2012 Sep 15; 434(1-2):306-14. PubMed ID: 22633931
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Role of ATP-binding cassette and solute carrier transporters in erlotinib CNS penetration and intracellular accumulation.
    Elmeliegy MA, Carcaboso AM, Tagen M, Bai F, Stewart CF.
    Clin Cancer Res; 2011 Jan 01; 17(1):89-99. PubMed ID: 21088257
    [Abstract] [Full Text] [Related]

  • 17. Breast cancer resistance protein (Bcrp/abcg2) is a major determinant of sulfasalazine absorption and elimination in the mouse.
    Zaher H, Khan AA, Palandra J, Brayman TG, Yu L, Ware JA.
    Mol Pharm; 2006 Jan 01; 3(1):55-61. PubMed ID: 16686369
    [Abstract] [Full Text] [Related]

  • 18. Mdr1a, Bcrp and Mrp2 regulate the efficacy and toxicity of mesaconitine and hypaconitine by altering their tissue accumulation and in vivo residence.
    Li X, Ou X, Luo G, Ou X, Xie Y, Ying M, Qu W, Zuo H, Qi X, Wang Y, Liu Z, Zhu L.
    Toxicol Appl Pharmacol; 2020 Dec 15; 409():115332. PubMed ID: 33171190
    [Abstract] [Full Text] [Related]

  • 19. Role of P-glycoprotein on the brain penetration and brain pharmacodynamic activity of the MEK inhibitor cobimetinib.
    Choo EF, Ly J, Chan J, Shahidi-Latham SK, Messick K, Plise E, Quiason CM, Yang L.
    Mol Pharm; 2014 Nov 03; 11(11):4199-207. PubMed ID: 25243894
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.